Advocacy intelligence hub — real-time data for patient organizations
Radboud University Medical Center — PHASE1, PHASE2
UNICANCER — NA
UNC Lineberger Comprehensive Cancer Center — NA
Region Skane
Centre Hospitalier Universitaire de Nīmes — NA
Fundacion Clinic per a la Recerca Biomédica — PHASE1
Izmir Ataturk Training and Research Hospital
Nimbus Wadjet, Inc. — PHASE1, PHASE2
University of Medicine and Pharmacy at Ho Chi Minh City
Sun Yat-sen University
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Qfitlia
Takeda Pharmaceuticals
Lumakras
(sotorasib)Orphan drugAmgen Inc.
12.1 Mechanism of Action Sotorasib is an inhibitor of KRAS G12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an...
Braftovi
(encorafenib)Orphan drugstandardArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)
12.1 Mechanism of Action Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays wi...
Avastin
(bevacizumab)Orphan drugstandardGenentech, Inc.
Vascular Endothelial Growth Factor Inhibitor [EPC]
12.1 Mechanism of Action Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial ce...
Stivarga
(regorafenib)Orphan drugstandardBayer HealthCare Pharmaceuticals, Inc.
12.1 Mechanism of Action Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular fu...
Tukysa
(tucatinib)Orphan drugacceleratedSeagen Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in...
CYRAMZA
(ramucirumab)Orphan drugstandardEli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
12.1 Mechanism of Action Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VE...
Erbitux
(cetuximab)Orphan drugstandardImClone Systems Incorporated
Epidermal Growth Factor Receptor Antagonist [EPC]
12.1 Mechanism of Action The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily o...
Fusilev
(levoleucovorin)Orphan drugstandardAcrotech Biopharma LLC
12.1 Mechanism of Action High-Dose Methotrexate Therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levole...
Michael Goggins, MD, MB BCh BAO
Johns Hopkins University
📍 PHILADELPHIA, PA
Robert BENAMOUZIG, Pr
Assistance Publique - Hôpitaux de Paris
Frank A Sinicrope, M.D
Alliance for Clinical Trials in Oncology
📍 ROCHESTER, MN
Ajay Bansal
University of Kansas
📍 KANSAS CITY, MO
Ann-Sofie Backman, MD PhD
Karolinska Institutet
Ann (Annie) W Silk
Dana-Farber - Harvard Cancer Center LAO
📍 Los Angeles, California